Related Experiment Video
Updated: Jan 10, 2026
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Antiviral clinical trial design throughout the COVID pandemic: evolving endpoints and lessons learnt
Beatrice Z Sim1,2,3, Andre C Kalil4, Cameron R Wolfe1
1Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA.
Purpose Of Review:
Trial design during the novel coronavirus-19 (COVID-19) pandemic was stymied by significant uncertainty about the natural history of the virus, at-risk populations, and optimal patient care by investigators and clinicians alike.
Recent Findings:
Three main types of trial design were invoked to address both the variable clinical disease and the evolving viral landscape, and to fit the respective health systems deploying the trials. These included adaptive trial design, platform trials, and master protocols. Strengths and challenges faced with each are discussed in more detail in the main text.
Summary:
Future pandemics will almost certainly continue to arise. Similarly, the landscape will continue to evolve alongside our understanding of the disease. Designing trials that remain scientifically rigorous and practical while still addressing the changing natural history of the disease continues to pose a challenge.
Insights
Clinical trial design faced challenges during the COVID-19 pandemic due to uncertainty. Adaptive, platform, and master protocols were used to address evolving disease and viral landscapes.
Area of Science:
- Infectious disease epidemiology
- Clinical trial methodology
- Pandemic preparedness
Background:
- The COVID-19 pandemic presented unprecedented challenges for clinical trial design.
- Uncertainty regarding the virus's natural history, at-risk populations, and optimal care impacted research.
- Existing trial frameworks required adaptation to navigate the evolving pandemic landscape.
Purpose of the Study:
- To review and analyze trial designs employed during the COVID-19 pandemic.
- To address the complexities of conducting research amidst significant scientific and healthcare system uncertainties.
- To evaluate strategies for maintaining scientific rigor and practicality in infectious disease research.
Main Methods:
- Review of adaptive trial designs.
- Analysis of platform trial methodologies.
- Examination of master protocol frameworks.
- Discussion of strengths and challenges associated with each design.
Main Results:
- Adaptive trial designs offered flexibility in response to evolving data.
- Platform trials enabled efficient evaluation of multiple interventions simultaneously.
- Master protocols streamlined the execution of multiple related studies.
- Each design type presented unique logistical and operational challenges.
Conclusions:
- Future pandemics necessitate adaptable and robust clinical trial designs.
- Integrating evolving scientific understanding with practical trial execution remains a critical challenge.
- Innovative trial methodologies are essential for effective pandemic response and future preparedness.
Related Concept Videos
01:20Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
01:11Clinical Trials: Overview
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
01:28Dosage Regimens: Designs and Approaches